Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27623
Title: | Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. | Austin Authors: | Lingvay, Ildiko;Sumithran, Priya ;Cohen, Ricardo V;le Roux, Carel W | Affiliation: | Diabetes Research Centre, Ulster University, Coleraine, UK The Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, São Paulo, Brazil Diabetes Complications Research Centre, Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland Division of Endocrinology, Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA Department of Medicine (St Vincent's Hospital), University of Melbourne, Melbourne, VIC, Australia Endocrinology |
Issue Date: | 2022 | Date: | 2021-09-30 | Publication information: | Lancet (London, England) 2022; 399(10322): 394-405 | Abstract: | Obesity is now recognised as a disease that is associated with serious morbidity and increased mortality. One of its main metabolic complications is type 2 diabetes, as the two conditions share key pathophysiological mechanisms. Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention. Furthermore, weight loss in this population exerts benefits that extend beyond glycaemic control to improve risk factors for cardiometabolic disease and quality of life. We review the evidence supporting the role of weight loss in the management of type 2 diabetes and propose that many patients with type 2 diabetes would benefit from having a primary weight-centric approach to diabetes treatment. We discuss the logistical challenges to implementing a new weight-centric primary treatment goal in people with type 2 diabetes. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27623 | DOI: | 10.1016/S0140-6736(21)01919-X | Journal: | Lancet | PubMed URL: | 34600604 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.